Johnson & Johnson (NYSE:JNJ) is Ironwood Investment Counsel LLC’s 9th Largest Position

Ironwood Investment Counsel LLC lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.6% in the third quarter, Holdings Channel reports. The firm owned 62,061 shares of the company’s stock after purchasing an additional 393 shares during the period. Johnson & Johnson makes up about 1.7% of Ironwood Investment Counsel LLC’s investment portfolio, making the stock its 9th biggest position. Ironwood Investment Counsel LLC’s holdings in Johnson & Johnson were worth $10,058,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of JNJ. EverSource Wealth Advisors LLC boosted its holdings in Johnson & Johnson by 64.7% in the 1st quarter. EverSource Wealth Advisors LLC now owns 14,509 shares of the company’s stock worth $2,098,000 after acquiring an additional 5,701 shares during the period. Park Place Capital Corp boosted its holdings in Johnson & Johnson by 37.9% in the 2nd quarter. Park Place Capital Corp now owns 4,864 shares of the company’s stock worth $711,000 after acquiring an additional 1,338 shares during the period. Davis Capital Management boosted its holdings in Johnson & Johnson by 9.3% in the 2nd quarter. Davis Capital Management now owns 9,991 shares of the company’s stock worth $1,463,000 after acquiring an additional 847 shares during the period. GAMMA Investing LLC boosted its holdings in Johnson & Johnson by 24.5% in the 2nd quarter. GAMMA Investing LLC now owns 25,592 shares of the company’s stock worth $3,741,000 after acquiring an additional 5,038 shares during the period. Finally, Hudson Valley Investment Advisors Inc. ADV raised its position in shares of Johnson & Johnson by 7.6% in the 2nd quarter. Hudson Valley Investment Advisors Inc. ADV now owns 15,904 shares of the company’s stock valued at $2,569,000 after purchasing an additional 1,121 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on JNJ. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 14th. Wolfe Research began coverage on Johnson & Johnson in a research report on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price on the stock. Wells Fargo & Company upped their target price on Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 16th. Royal Bank of Canada upped their target price on Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research report on Wednesday, October 16th. Finally, Citigroup upped their target price on Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a research report on Wednesday, October 16th. Seven research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $175.94.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $155.08 on Friday. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $168.85. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The business’s fifty day moving average price is $159.15 and its two-hundred day moving average price is $156.40. The firm has a market capitalization of $373.37 billion, a PE ratio of 22.44, a P/E/G ratio of 2.76 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. During the same period last year, the company earned $2.66 earnings per share. The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. On average, research analysts expect that Johnson & Johnson will post 9.93 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be paid a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 annualized dividend and a dividend yield of 3.20%. Johnson & Johnson’s payout ratio is 71.78%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.